Fig. 2

CircNFAT5 expression levels in 542 patients of the TTM-trial. CircNFAT5 levels were compared according to the temperature regimen and regardless of the neurological outcome (a), between females and males (b), between good (CPC 1–2) and poor (CPC 3–5) neurological outcome regardless of the temperature regimen (c), and separately in patients treated at 36 °C or 33 °C (d, e). The expression levels of circNFAT5 were normalized, log2 transformed and scaled. p-values are from Mann–Whitney U test